Champions Oncology Inc Stock OTC Bulletin Board
Equities
US15870P1093
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 15 | Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023. | CI |
Mar. 13 | Craig-Hallum Downgrades Champions Oncology to Hold From Buy | MT |
Financials (USD)
Sales 2024 * | 48.84M | Sales 2025 * | 53.68M | Capitalization | 68.78M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 1.41 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.28 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.79% |
Latest transcript on Champions Oncology Inc
Managers | Title | Age | Since |
---|---|---|---|
Ronnie Morris
CEO | Chief Executive Officer | 58 | 10-10-25 |
Brady Davis
PSD | President | - | 23-10-16 |
Joel Ackerman
CHM | Chairman | 59 | 10-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Sidransky
FOU | Founder | 64 | 07-12-31 |
Scott Tobin
BRD | Director/Board Member | 53 | 11-06-26 |
Joel Ackerman
CHM | Chairman | 59 | 10-10-25 |
1st Jan change | Capi. | |
---|---|---|
+1.85% | 42.59B | |
+8.05% | 40.65B | |
+48.83% | 40.57B | |
-11.96% | 26.77B | |
+8.75% | 24.81B | |
-24.35% | 18.17B | |
+28.11% | 12.05B | |
-2.97% | 11.7B | |
+7.59% | 11.1B |